Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against ... - Reuters |
 |
 |
|
ReutersPatients with moderate renal impairment (CrCL = 20-39 mL/min) should receive a 50% decrease in the recommended starting dose, and future doses can be ...Tasigna - Novartis drug Tasigna® meets primary endpoint in pivotal trial ... read more |
